These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 477712)

  • 1. Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease.
    Friis ML; Grøn U; Larsen NE; Pakkenberg H; Hvidberg EF
    Eur J Clin Pharmacol; 1979 May; 15(4):275-80. PubMed ID: 477712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.
    Friis ML; Johnsen T; Larsen NE; Hvidberg EF; Pakkenberg H
    Eur J Clin Pharmacol; 1980 Aug; 18(2):171-4. PubMed ID: 7428799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist substitution in advanced Parkinson's disease.
    Goetz CG; Shannon KM; Tanner CM; Carroll VS; Klawans HL
    Neurology; 1989 Aug; 39(8):1121-2. PubMed ID: 2761708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.
    Price P; Debono A; Parkes JD; Marsden CD; Rosenthaler J
    Br J Clin Pharmacol; 1978 Oct; 6(4):303-9. PubMed ID: 359016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of bromocriptine in plasma: comparison of gas chromatography, mass fragmentography and liquid chromatography.
    Larsen NE; Ohman R; Larsson M; Hvidberg EF
    J Chromatogr; 1979 Jul; 174(2):341-9. PubMed ID: 546893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of Parkinson's disease with bromocriptine.
    Rascol A; Guiraud B; Montastruc JL; David J; Clanet M
    J Neurol Neurosurg Psychiatry; 1979 Feb; 42(2):143-50. PubMed ID: 422961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.